Clinical Ink announced that it entered into a collaboration with Tandem Diabetes Care to integrate (AID) data.

Our study assessed the impact of using Control-IQ technology, an automated insulin delivery system, on achievement of a Healthcare Effectiveness Data and Information Set (HEDIS) quality measure ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it launched its t:slim mobile application for Android and iOS users in Canada.

Tandem Diabetes Care's top-line growth hasn't been great over the past few years. If it can successfully address challenges detrimental to revenue growth, it may become an attractive stock -- even ...

Tandem Diabetes Care, Inc.’s TNDM impressive international expansion is expected to bolster growth in the upcoming quarters. The company’s impressive strategic initiatives provide a favorable ...

Rosen Law Firm’s probe into Tandem Diabetes Care (TNDM) after a voluntary correction of certain t:slim X2 insulin pumps, and the roughly 20% share drop that followed, has investors reassessing risk ...

Tandem Diabetes Care ( (TNDM)) has issued an announcement. On November 7, 2025, Tandem Diabetes Care appointed Sandra Beaver to its Board of Directors, expanding the board from eight to nine members.

Tandem Diabetes Care, an insulin delivery and diabetes technology company, announced it received FDA clearance for the Android version of its mobile app Tandem Mobi. The system, powered by Control-IQ ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2025 and reaffirmed full ...

During the last three months, 13 analysts shared their evaluations of Tandem Diabetes Care (NASDAQ:TNDM), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...